Alto Neuroscience (NYSE:ANRO) Sets New 12-Month High - Should You Buy?

Key Points

• Alto Neuroscience shares reached a new 52-week high, trading as high as $29.49 and closing near $29.19, up from the prior close of $28.03.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $35.25, although Zacks Research downgraded the stock to “Strong Sell.”
• The clinical-stage biotech reported a quarterly loss of $0.80 per share, missing estimates of a $0.56 loss, while analysts expect a full-year loss of $3.14 per share.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report)'s stock price reached a new 52-week high on Thursday . The stock traded as high as $29.49 and last traded at $29.1860, with a volume of 94860 shares trading hands. The stock had previously closed at $28.03.

Wall Street Analyst Weigh In

ANRO has been the topic of several research analyst reports. Zacks Research lowered shares of Alto Neuroscience from a "hold" rating to a "strong sell" rating in a research note on Wednesday, July 22nd. Robert W. Baird decreased their price target on shares of Alto Neuroscience from $38.00 to $36.00 and set an "outperform" rating for the company in a research note on Monday, May 18th. Wolfe Research began coverage on shares of Alto Neuroscience in a report on Friday, May 22nd. They set an "outperform" rating on the stock. Bank of America assumed coverage on shares of Alto Neuroscience in a research report on Tuesday, May 5th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Chardan Capital reissued a "buy" rating and set a $30.00 price objective on shares of Alto Neuroscience in a research report on Wednesday, April 22nd. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Alto Neuroscience presently has an average rating of "Moderate Buy" and a consensus target price of $35.25.

Alto Neuroscience Price Performance

The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The business has a 50-day moving average price of $24.53 and a two-hundred day moving average price of $22.17. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -11.92 and a beta of 1.06.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.24). As a group, research analysts anticipate that Alto Neuroscience, Inc. will post -3.14 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Torren Management LLC acquired a new stake in shares of Alto Neuroscience in the 4th quarter worth about $62,000. GK Wealth Management LLC acquired a new position in Alto Neuroscience during the 2nd quarter valued at about $226,000. Balyasny Asset Management L.P. acquired a new position in Alto Neuroscience during the 4th quarter valued at about $198,000. OMERS ADMINISTRATION Corp bought a new stake in Alto Neuroscience during the 4th quarter worth approximately $221,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Alto Neuroscience during the 4th quarter worth approximately $304,000.

Alto Neuroscience Company Profile

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source